



## PHARMACEUTICAL 2018











## PHARMACEUTICAL 2018



## Aclaris Therapeutics Inc. Rank 32 of 342



The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 198% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	200,221
Cost of Goods Sold	1,207
Intangible Assets	25,853
Liabilities, Current	12,762
Liabilities, Non-Current	558
Other Assets	15,276
Other Compr. Net Income	23
Other Expenses	-1,830
Other Liabilities	4,927
Other Net Income	2,070
Other Revenues	1,683
Property and Equipment	2,159
Research and Development	39,790
Selling, General and Administrative Expense	33,109

Output Variable	Value in 1000 USD
Assets	243,509
Liabilities	18,247
Expenses	72,276
Revenues	1,683
Stockholders Equity	225,262
Net Income	-68,523
Comprehensive Net Income	-68,512
Economic Capital Ratio	244%

